硅谷银行（SVB）：2024年医疗健康行业投资与退出趋势年度报告（英文版）（34页）.pdf

1、Published January 7,2025AI doesnt change the fact that establishing therapeutic effectiveness in human beings remains unpredictable and time-consuming.If bigger,deeper datasets are the Holy Grail for AI companies,tools to improve and accelerate clinical trials are the Holy Grail for biotech.”HEALTHC

2、ARE INVESTMENTS&EXITS|ANNUAL REPORT 20242Another year begins,and so we bring you our Healthcare Investments and Exits 2024 report.After a few years of uncertainty and noise,were starting to get signals about where healthcare innovation is headed over the next 10 years.Biopharma AI is the story of 20

3、24.Overall investment in the space has exploded despite the headwinds still facing the innovation economy.The biggest impacts of AI in life science and biotech are still emerging.Clinical trials are a long,difficult process.A new drug candidate found today wont be available as a product for at least

4、 five years.That means investors wanting in on the cutting edge of commercial AI biotech need to be investing now.The success of AI companies in attracting investment,even in an environment insisting that companies demonstrate real value and results,shows the premium investors are placing on long-te

5、rm transformation in biopharma.The first entirely AI-designed drugs are moving through clinical trials that started in 2020.With those readouts coming up,2025 will be a long-awaited“prove-it”year for AI drug discovery.One of the most exciting use cases for AI is in novel protein development.Venture

6、funding into AI-driven protein design has skyrocketed alongside a shared Nobel Prize in Chemistry driven by work at the Institute for Protein Design and at Google DeepMind.The jump was mostly driven by a mammoth$1B Series A round given to Xaira,a company thats been in existence for less than two yea